A Safety and feasibility study of standard dosing day 1 carboplatin AUC 5 every 3rd weeks with daily Navelbine® 20/30mg (oral) during 4 cycles (12 weeks) for the treatment of advanced NSCLC; A feasibility study (Sikkerheds- og effektstudie af standard (st.) dosering af carboplatin dag 1 hver 3. uge plus daglig Navelbine® 20/30 mg (oral) i lØbet af 4 cykler (12 uger) til behandling af fremskreden ikke små-cellet lungekræft; Et pilot studie)

Trial Profile

A Safety and feasibility study of standard dosing day 1 carboplatin AUC 5 every 3rd weeks with daily Navelbine® 20/30mg (oral) during 4 cycles (12 weeks) for the treatment of advanced NSCLC; A feasibility study (Sikkerheds- og effektstudie af standard (st.) dosering af carboplatin dag 1 hver 3. uge plus daglig Navelbine® 20/30 mg (oral) i lØbet af 4 cykler (12 uger) til behandling af fremskreden ikke små-cellet lungekræft; Et pilot studie)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NavMetro protocol
  • Most Recent Events

    • 13 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top